Aurinia Pharmaceuticals Celebrates Approval of LUPKYNIS in Japan
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is thrilled to share that voclosporin, branded as LUPKYNIS, has received official approval from the Japanese Ministry of Health, Labour, and Welfare for the treatment of lupus nephritis (LN). This is a significant milestone that enhances treatment access for lupus patients across Japan.
Collaboration with Otsuka Pharmaceutical
This approval is the result of a partnership with Otsuka Pharmaceutical Co., Ltd., which filed the new drug application (NDA) in November 2023. The decision is based on extensive data from the AURORA Clinical Program, including a crucial 12-month Phase 3 study along with a subsequent two-year extension study. These studies evaluated how effective and safe LUPKYNIS is when used with mycophenolate mofetil (MMF) and low-dose glucocorticoids compared to using MMF and low-dose glucocorticoids alone.
Addressing a Critical Need for Lupus Nephritis
Peter Greenleaf, President and Chief Executive Officer of Aurinia, expressed his excitement upon hearing the approval news. "We are delighted to reach this milestone, which allows patients in Japan to access LUPKYNIS, especially since there is a high prevalence of lupus nephritis among Japanese lupus patients. Our effective strategic partnership has enabled us to provide LUPKYNIS to LN patients in several regions, including Europe and now Japan. This really meets a crucial need for individuals battling this challenging disease," he commented.
Benefits of the Collaboration Agreement
Aurinia’s partnership with Otsuka includes a comprehensive licensing agreement established in December 2020. As part of this agreement, Aurinia is set to receive $10 million in payments upon Japan’s approval, along with low double-digit royalties on net sales following the launch. This strategic collaboration facilitates Aurinia's capacity to supply Otsuka, ensuring an effective launch strategy.
LUPKYNIS: Pioneering Treatment for Lupus Nephritis
Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that impacts many lives. This condition significantly affects individuals, especially women and people of color, with approximately 120,000 diagnosed in the U.S. alone. If not effectively managed, uncontrolled lupus nephritis can result in irreversible kidney damage, making timely treatment vital.
Importance of Routine Screening and Early Treatment
Medical guidelines strongly recommend routine screenings for LN for all SLE patients during their healthcare visits. However, studies show that about 50% of SLE patients fail to get the necessary screenings for LN. Aurinia is committed to improving health outcomes for these individuals by focusing on educating both patients and healthcare providers about the importance of regular screenings and the availability of transformative treatments.
The Unique Mechanism of LUPKYNIS
LUPKYNIS is known as a second-generation calcineurin inhibitor that works through a dual approach: it serves as an immunosuppressant by inhibiting T-cell activation and cytokine production, while also enhancing the stability of podocytes within the kidneys. Clinical trials have shown that LUPKYNIS, when combined with standard care, can help safeguard kidney health without the need for high doses of glucocorticoids, which is a key consideration in treating lupus nephritis.
Aurinia’s Commitment to Autoimmune Disease Treatment
Aurinia Pharmaceuticals is dedicated to creating innovative therapies for autoimmune diseases with significant unmet clinical needs. In addition to LUPKYNIS, the company is developing AUR200, a promising therapy that targets both BAFF and APRIL, and could redefine care standards in treating autoimmune conditions.
Frequently Asked Questions
What is lupus nephritis?
Lupus nephritis is a serious kidney condition resulting from systemic lupus erythematosus, potentially leading to kidney damage if not properly treated.
Who is eligible to receive LUPKYNIS?
LUPKYNIS is approved for adult patients diagnosed with active lupus nephritis, to be used alongside standard immunosuppressive therapy.
Why is LUPKYNIS significant for lupus nephritis patients?
LUPKYNIS offers a new treatment solution that may enhance kidney health while reducing dependence on high doses of glucocorticoids.
What potential side effects are associated with LUPKYNIS?
Common side effects may include hypertension, renal impairment, and infections, necessitating consistent monitoring throughout treatment.
How does Aurinia plan to educate healthcare providers about LUPKYNIS?
Aurinia is focused on educating healthcare providers regarding the critical nature of routine LN screenings and the advantages of LUPKYNIS in improving patient outcomes.
